- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05952869
A Study of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017) CORALreef HeFH
March 12, 2024 updated by: Merck Sharp & Dohme LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia
The goal of this study is to evaluate the efficacy, safety, and tolerability of MK-0616 in adult participants with heterozygous familial hypercholesterolemia.
The primary hypothesis is that MK-0616 is superior to placebo on mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
270
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Toll Free Number
- Phone Number: 1-888-577-8839
- Email: Trialsites@merck.com
Study Locations
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Royal Prince Alfred Hospital-6West CV Ambulatory Care ( Site 2808)
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Victorian Heart Hospital-Monash Cardiovascular Research Centre (MCRC) ( Site 2803)
-
-
-
-
-
Sao Paulo, Brazil, 05403-000
- Incor - Instituto do Coracao ( Site 0703)
-
-
Ceara
-
Fortaleza, Ceara, Brazil, 60430-270
- Universidade Federal Do Ceara ( Site 0702)
-
-
Sao Paulo
-
São Paulo, Sao Paulo, Brazil, 04012-909
- Instituto Dante Pazzanese de Cardiology-Fundação Adib Jatene ( Site 0701)
-
-
-
-
Quebec
-
Chicoutimi, Quebec, Canada, G7H 7K9
- Ecogene-21 ( Site 0510)
-
Montreal, Quebec, Canada, H1T 1C8
- Institut de Cardiologie de Montreal ( Site 0506)
-
Trois-Rivieres, Quebec, Canada, G9A 4P3
- Diex Recherche Trois-Rivieres ( Site 0513)
-
-
-
-
Los Rios
-
Valdivia, Los Rios, Chile, 5110683
- Clinical Research Chile SpA ( Site 0804)
-
-
Region M. De Santiago
-
Providencia, Region M. De Santiago, Chile, 7500859
- CDIEM ( Site 0814)
-
Santiago, Region M. De Santiago, Chile, 7500587
- Enroll SpA ( Site 0803)
-
Santiago, Region M. De Santiago, Chile, 8330034
- Pontificia Universidad Catolica de Chile-CICUC ( Site 0812)
-
-
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 050021
- Fundación Centro de Investigación Clínica CIC ( Site 0906)
-
-
Atlantico
-
Barranquilla, Atlantico, Colombia, 08001
- Ciensalud Ips S A S ( Site 0903)
-
Barranquilla, Atlantico, Colombia, 080020
- Clinica de la Costa S.A.S. ( Site 0902)
-
-
Cundinamarca
-
Bogotá, Cundinamarca, Colombia, 110231
- Salud SURA Calle 100 ( Site 0918)
-
-
-
-
Brno-mesto
-
Brno, Brno-mesto, Czechia, 625 00
- Fakultní nemocnice Brno Bohunice-Interni kardiologicka klinika ( Site 3602)
-
-
Jihomoravsky Kraj
-
Brno, Jihomoravsky Kraj, Czechia, 60200
- Fakultni Nemocnice u sv. Anny v Brne ( Site 3604)
-
-
Praha 4
-
Praha, Praha 4, Czechia, 140 21
- Institut Klinicke a Experimentalni Mediciny ( Site 3601)
-
-
-
-
Uusimaa
-
Helsinki, Uusimaa, Finland, 00290
- Meilahden tornisairaala - Meilahti Tower Hospital ( Site 1300)
-
-
-
-
-
Pok Fu Lam, Hong Kong
- Queen Mary Hospital-Medical ( Site 3300)
-
Shatin, Hong Kong, NT
- Prince of Wales Hospital ( Site 3304)
-
-
-
-
-
Budapest, Hungary, 1122
- Semmelweis Egyetem-Városmajori Szív- és Érgyógyászati Klinika ( Site 1600)
-
Debrecen, Hungary, 4032
- Debreceni Egyetem Klinikai Kozpont-Belgyógyászati Klinika (Anyagcsere Tanszék) ( Site 1601)
-
-
Csongrad
-
Szeged, Csongrad, Hungary, 6725
- Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Belgyógyászati Klinika ( Site 1603)
-
-
-
-
-
Jerusalem, Israel, 9103102
- Shaare Zedek Medical Center ( Site 1710)
-
Jerusalem, Israel, 9112001
- Hadassah Medical Center ( Site 1709)
-
Petah Tikva, Israel, 4941492
- Rabin Medical Center ( Site 1717)
-
Sakhnin, Israel, 308100
- Clalit Health Services - Sakhnin Community Clinic-Research Unit ( Site 1700)
-
-
-
-
-
Utrecht, Netherlands, 3584 CX
- Universitair Medisch Centrum Utrecht-Vascular Medicine Research ( Site 1955)
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6525 GA
- Radboudumc-internal medicine ( Site 1952)
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1105 AZ
- Amsterdam UMC, locatie AMC-Vascular Medicine Clin Trial Unit ( Site 1954)
-
Hoorn, Noord-Holland, Netherlands, 1625 HV
- Vasculair Onderzoek Centrum Hoorn ( Site 1953)
-
-
-
-
Bay Of Plenty
-
Rotorua, Bay Of Plenty, New Zealand, 3010
- Pacific Clinical Research Network - Rotorua ( Site 2902)
-
-
Canterbury
-
Christchurch, Canterbury, New Zealand, 8011
- New Zealand Clinical Research (Christchurch) ( Site 2901)
-
-
-
-
-
Oslo, Norway, 0316
- Oslo Universitetssykehus Aker-Lipidklinikken ( Site 2000)
-
-
Nordland
-
Bodø, Nordland, Norway, 8005
- Nordlandssykehuset ( Site 2001)
-
-
-
-
Central Singapore
-
Singapore, Central Singapore, Singapore, 119074
- National University Hospital-Department of Medicine ( Site 3212)
-
Singapore, Central Singapore, Singapore, 529889
- Changi General Hospital ( Site 3211)
-
-
-
-
Cataluna
-
Sant Joan Despí, Cataluna, Spain, 08970
- Hospital de Sant Joan Despí Moisès Broggi ( Site 2335)
-
-
Tarragona
-
Reus, Tarragona, Spain, 43204
- SALUT SANT JOAN DE REUS-BAIX CAMP (EDP)-Vascular and Metabolism Unit ( Site 2329)
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, Spain, 46010
- HOSPITAL CLINICO DE VALENCIA ( Site 2321)
-
-
-
-
-
Tainan, Taiwan, 704
- National Cheng Kung University Hospital-Internal Medicine ( Site 3107)
-
Taipei, Taiwan, 10002
- National Taiwan University Hospital ( Site 3100)
-
-
New Taipei
-
New Taipei City, New Taipei, Taiwan, 251
- Mackay Memorial Hospital -Tamshui Branch ( Site 3109)
-
-
Taipei
-
Taipei City, Taipei, Taiwan, 111
- Shin Kong Wu Ho-Su Memorial Hospital ( Site 3106)
-
-
-
-
Alabama
-
Daphne, Alabama, United States, 36526
- Alliance for Multispecialty Research, LLC ( Site 0023)
-
-
Florida
-
Boca Raton, Florida, United States, 33434
- Excel Medical Clinical Trials ( Site 0008)
-
Cutler Bay, Florida, United States, 33189
- Advanced Pharma Research ( Site 0007)
-
Port Orange, Florida, United States, 32127
- Progressive Medical Research ( Site 0021)
-
Winter Park, Florida, United States, 32789
- Clinical Site Partners LLC, dba CSP Orlando ( Site 0028)
-
-
Indiana
-
Evansville, Indiana, United States, 47714
- Synexus Clinical Research US - Evansville ( Site 0031)
-
Indianapolis, Indiana, United States, 46237
- Franciscan Physician Network - Indiana Heart Physicians ( Site 0040)
-
-
Michigan
-
Troy, Michigan, United States, 48098
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0001)
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68506
- Velocity Clinical Research at The Pioneer Heart Institute, Lincoln ( Site 0026)
-
-
Nevada
-
Las Vegas, Nevada, United States, 89106
- Jubilee Clinical Research ( Site 0030)
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Baptist Health-Cardiovascular Medicine ( Site 0041)
-
-
Utah
-
West Jordan, Utah, United States, 84088
- Velocity Clinical Research, Salt Lake City ( Site 0004)
-
-
Virginia
-
Newport News, Virginia, United States, 23606
- Health Research of Hampton Roads, Inc. ( Site 0020)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Has possible or definite diagnosis of heterozygous familial hypercholesterolemia (HeFH) based on a locally accepted diagnostic algorithm
- Has an LDL-C ≥55 mg/dL or ≥70 mg/dL depending on medical history
- Is treated with a moderate- or high-intensity statin medication
- Is on a stable dose of all background lipid-lowering therapies (LLTs) with no planned medication change
Exclusion Criteria:
- Has a history of homozygous familial hypercholesterolemia (FH) based on genetic or clinical criteria, compound heterozygous FH, or double heterozygous FH
- Has a history of heart failure or heart failure hospitalization within 3 months before first study visit
- Is undergoing or previously underwent an LDL-C apheresis program within 3 months before first study visit or plans to initiate an LDL-C apheresis program
- Was previously treated/is being treated with certain other cholesterol lowering medications, including protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MK-0616
Participants will receive 20 mg of MK-0616 orally once daily (QD) for up to 52 weeks.
|
Oral tablet
|
Placebo Comparator: Placebo
Participants will receive MK-0616-matching placebo orally QD for up to 52 weeks.
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24
Time Frame: Baseline and Week 24
|
Blood samples will be collected at baseline and at Week 24 to assess mean percent change in LDL-C.
|
Baseline and Week 24
|
Number of participants with one or more adverse events (AEs)
Time Frame: Up to ~60 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
|
Up to ~60 weeks
|
Number of participants who discontinue study drug due to an AE
Time Frame: Up to ~52 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
|
Up to ~52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean percent change from baseline in LDL-C at Week 52
Time Frame: Baseline and Week 52
|
Blood samples will be collected at baseline and at Week 52 to assess mean percent change in LDL-C.
|
Baseline and Week 52
|
Mean percent change from baseline in apolipoprotein B (ApoB) at Week 24
Time Frame: Baseline and Week 24
|
Blood samples will be collected at baseline and at Week 24 to assess mean percent change in ApoB.
|
Baseline and Week 24
|
Percent change from baseline in lipoprotein(a) (Lp[a]) at Week 24
Time Frame: Baseline and Week 24
|
Blood samples will be collected at baseline and at Week 24 to assess percent change in Lp(a).
|
Baseline and Week 24
|
Percentage of participants with LDL-C <70 mg/dL and ≥50% reduction from baseline at Week 24
Time Frame: Baseline and Week 24
|
Blood samples will be collected at baseline and at Week 24 to assess the percentage of participants who have LDL-C <70 mg/dL and ≥50% reduction from baseline.
|
Baseline and Week 24
|
Percentage of participants with LDL-C <55 mg/dL and ≥50% reduction from baseline at Week 24
Time Frame: Baseline and Week 24
|
Blood samples will be collected at baseline and at Week 24 to assess the percentage of participants who have LDL-C <55 mg/dL and ≥50% reduction from baseline.
|
Baseline and Week 24
|
Mean percent change from baseline in non-high-density lipoprotein cholesterol (HDL-C) at Week 24
Time Frame: Baseline and Week 24
|
Blood samples will be collected at baseline and at Week 24 to assess mean percent change in non-HDL-C.
|
Baseline and Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 8, 2023
Primary Completion (Estimated)
April 28, 2025
Study Completion (Estimated)
April 28, 2025
Study Registration Dates
First Submitted
July 10, 2023
First Submitted That Met QC Criteria
July 10, 2023
First Posted (Actual)
July 19, 2023
Study Record Updates
Last Update Posted (Actual)
March 13, 2024
Last Update Submitted That Met QC Criteria
March 12, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0616-017
- MK-0616-017 (Other Identifier: Merck)
- 2022-502782-14 (Registry Identifier: EU CT)
- U1111-1285-4257 (Other Identifier: UTN)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Direct PlantesUnknownHYPERCHOLESTEROLEMIAFrance
-
Chong Kun Dang PharmaceuticalRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Addpharma Inc.CompletedPrimary HypercholesterolemiaKorea, Republic of
-
JW PharmaceuticalCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Provident Clinical ResearchGlaxoSmithKlineUnknownPrimary HypercholesterolemiaUnited States
-
Boryung Pharmaceutical Co., LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Ahn-Gook Pharmaceuticals Co.,LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Jiangsu HengRui Medicine Co., Ltd.CompletedPrimary HypercholesterolemiaChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States